The first child has been vaccinated in The Gambia with the company’s ETEC vaccine candidate, ETVAX.
It is a randomised, placebo-controlled, and double-blind phase IIB study. The study will include about 5,000 children aged 6-23 months. The overall goal of the study is to investigate the protective effect against moderate to severe diarrhoea caused by ETEC over a 1- to 2-year period.
“It feels great that we are up and running. A big thanks to everyone who made this possible during the ongoing pandemic,” says Anna Hill who is Clinical Operations Manager for Scandinavian Biopharma.
“Now we are approaching the goal of developing a vaccine that can really make a difference. It is especially important to improve children’s chances of winning the battle against life-threatening diarrhoea caused by ETEC,” says Björn Sjöstrand, CEO of Scandinavian Biopharma.
Photo of Anna Hill: Scandinavian Biopharma